Groundbreaking Trial Launches for Innovative Cancer Drug M1231
A groundbreaking clinical trial has begun in Texas and Canada, testing a novel antibody-based drug, M1231, for hard-to-treat cancers. The study, led by BioInvent, aims to assess the safety of this innovative treatment for patients with advanced tumors.
M1231, a bispecific antibody, is designed to target cancer cells more effectively than previous antibody-based drugs. It has two 'arms', one developed at the Technical University of Brunswick and the other based on Merck's Erbitux. This unique structure allows M1231 to recognize and bind to two features on cancer cells, improving its targeting and combating functions.
Once bound to cancer cells, M1231 activates the body's immune system and releases a pharmaceutical agent directly into the tumor, inhibiting its growth. This innovative approach is made possible by a human antibody invention from the Technical University of Brunswick.
The Phase 1/2 clinical trial (NCT04695847) is investigating M1231's safety in patients with metastatic solid tumors, esophageal cancer, and non-small cell lung cancer. BioInvent, the developer of BI-1910, a TNFR2 agonist for solid tumors, is conducting the study. They recently completed a Phase 1 dose escalation study for BI-1910 with no significant side effects, indicating promising potential for M1231.
The first patients in the USA are now being treated with M1231 as part of this clinical trial. If proven safe and effective, this novel antibody-based medication could significantly improve treatment options for patients with advanced tumors.
